Lilly reports positive data from new Cialis trial

Lilly has reported positive new clinical trial data from a study of Cialis, its therapy for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH).

Results from the phase III trial showed that the drug was able to meet its co-primary endpoints of providing significant clinical improvements for men suffering from both conditions, compared to placebo.

The trial was the first to evaluate the therapy among an exclusively male patient population, with 606 subjects from nine different countries evaluated over a period of 12 weeks.

Data from this study will be used to support regulatory applications that Lilly has made for approval of the therapy against both conditions.

Dr Anthony Beardsworth, Lilly's senior medical director, said: "Lilly is committed to research that can help us offer new treatment options and advance our understanding of ED and BPH, conditions that affect millions of men worldwide."

This comes after the firm received a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use last month for its drug Alimta to be used as a continuation maintenance therapy for lung cancer.